Clinical Trial Update: Myrcludex B in Combination With Peginterferon Alfa-2a Versus Peginterferon Alfa-2a Alone in Patients With Chronic Viral Hepatitis B With Delta-agent [Phase 2]

View source ↗

Summary

Phase 2 trial comparing Myrcludex B plus peginterferon alfa-2a versus peginterferon alfa-2a alone in chronic hepatitis B with delta-agent; results posted after …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Delta Agent-associated Hepatitis
• Hepatitis B
• Hepatitis D

Drugs mentioned

• Myrcludex B (bulevirtide)
• Peginterferon alfa-2a (peginterferon alfa-2a)

Snippet

Sponsor: Hepatera Ltd. | Conditions: Chronic Viral Hepatitis B With Delta-agent | Phase 2 | Status: COMPLETED | Results posted: 2021-02-25